Clinical pharmacokinetics and pharmacodynamics of vildagliptin

Clinical Pharmacokinetics

Volumn 51, Issue 3, 2012, Pages 147-162

  He, Yan Ling ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Antihyperglycaemics; CD26 antigen inhibitors; Pharmacokinetics; Pharmacology; Type 2 diabetes mellitus; Vildagliptin.

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GLIBENCLAMIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; RAMIPRIL; SIMVASTATIN; SULFONYLUREA; VALSARTAN; VILDAGLIPTIN; WARFARIN;

AGE DISTRIBUTION; AREA UNDER THE CURVE; BODY MASS; CELL FUNCTION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERANCE; ETHNICITY; GENDER; GLOMERULUS FILTRATION RATE; GLUCAGON BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RELEASE; INTERNATIONAL NORMALIZED RATIO; INTRAVENOUS GLUCOSE TOLERANCE TEST; KIDNEY CLEARANCE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE;

ADAMANTANE; ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; NITRILES; PATIENT SELECTION; PYRROLIDINES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84863115894     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11598080-000000000-00000     Document Type: Review

References (131)

1. Nathan DM, Buse JB, Davidson MB, et al., American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32 (1): 193-203
2. Elliott RM, Morgan LM, Tredger JA, et al. Glucagon-like peptide-1 (7-36) amide and glucose-dependent insulintropic polypeptide secretion in response to nutrient ingestion in man: acute postprandial and 24-h secretion patterns. J Endocrinol 1993; 138: 159-66 (Pubitemid 23266831)
3. Kreymann B, Williams G, Ghatei MA, et al. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987; 2: 1300-4 (Pubitemid 17156636)
4. Nauck MA, Bartels E, Orskov C, et al. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993; 76 (4): 912-7 (Pubitemid 23110837)
5. Nauck MA, Bartels E, Orskov C, et al. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 1998; 21 (11): 1925-31 (Pubitemid 28478295)
6. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (noninsulin-dependent) diabetic patients. Diabetologia 1993; 36 (8): 741-4 (Pubitemid 23218642)
7. Deacon CF. What do we know about the secretion and degradation of incretin hormones? Regul Pept 2005 Jun 15; 128 (2): 117-24 (Pubitemid 40380912)
8. Naslund E, Bogefors J, Skogar S, et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 1999; 277 (3 Pt 2): R910-6 (Pubitemid 29458166)
9. Delgado-Aros S, Kim DY, Burton DD, et al. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol 2002; 282 (3): G424-31 (Pubitemid 34651657)
10. Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and betacell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359 (9309): 824-30 (Pubitemid 34233752)
11. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagonlike peptide-1. Diabetes Metab Res Rev 2002; 18 (6): 430-41 (Pubitemid 36041598)
12. Nystrom T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004 Dec; 287 (6): E1209-15
13. Gutniak MK, Linde B, Holst JJ, et al. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 1994; 17 (9): 1039-44 (Pubitemid 24268617)
14. Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res 2004; 36 (11-12): 761-5 (Pubitemid 40115896)
15. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214 (3): 829-35 (Pubitemid 23188160)
16. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80 (3): 952-7
17. Abbott CA, Baker E, Sutherland GR, et al. Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics 1994; 40 (5): 331-8 (Pubitemid 24299322)
18. Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995 Sep; 44 (9): 1126-31
19. Deacon CF. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004; 53 (9): 2181-9 (Pubitemid 39145569)
20. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368 (9548): 1696-705 (Pubitemid 46048557)
21. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010; 12 (8): 648-58
22. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 2011; 71 (11): 1441-67
23. Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010; 12 (9): 780-9
24. Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50 (6): 1148-55 (Pubitemid 46701545)
25. Ahren B, Pacini G, Foley JE, et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005; 28: 1936-40 (Pubitemid 41060966)
26. Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30 (4): 890-5 (Pubitemid 46556583)
27. Ahrén B, Foley JE, Bosi E. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 2011; 13 (3): 193-203
28. Pratley RE, Jauffret-Kamel S, Galbreath E, et al. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006; 38 (6): 423-8 (Pubitemid 44047965)
29. Ahren B, Gomis R, Standl E, et al. Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27 (12): 2874-80 (Pubitemid 39565052)
30. Ristic S, Byiers S, Foley J, et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005; 7: 692-8 (Pubitemid 41601073)
31. Dejager S, Razac S, Foley JE, et al. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007; 39 (3): 218-23 (Pubitemid 46580622)
32. Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007; 30 (2): 217-23 (Pubitemid 46198322)
33. Pi-Sunyer FX, Schweizer A, Mills D, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007 Apr; 76 (1): 132-8 (Pubitemid 46240373)
34. Schweizer A, Dejager S, Foley JE, et al. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ‡75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab 2011; 13 (1): 55-64
35. Iwamoto Y, Kashiwagi A, Yamada N, et al. Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. Diabetes Obes Metab 2010; 12 (8): 700-8
36. Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008; 25 (4): 435-41 (Pubitemid 351490110)
37. Rosenstock J, Baron MA, Camisasca RP, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9 (2): 175-85 (Pubitemid 46206561)
38. Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007; 9 (2): 166-74 (Pubitemid 46206560)
39. Derosa G, Maffioli P, Ferrari I, et al. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Horm Metab Res 2010; 42 (9): 663-9
40. He YL, Barilla D, Ligureos-Saylan M, et al. The pharmacokinetics and DPP-4 inhibition of LAF237 in healthy volunteers [abstract]. J Clin Pharmacol 2004; 44: 1212
41. Sunkara G, Sabo R, He YL, et al. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. J Clin Pharmacol 2007; 47 (9): 1152-8
42. He YL, Serra D, Wang Y, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet 2007; 46 (7): 577-88 (Pubitemid 47025358)
43. He YL, Sabo R, Sunkara G, et al. Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers. J Clin Pharmacol 2007; 47 (8): 998-1004 (Pubitemid 47094094)
44. He YL, Sabo R, Riviere GJ, et al. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin 2007; 23: 1131-8 (Pubitemid 46799597)
45. He YL, Sadler BM, Sabo R, et al. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet 2007; 46 (9): 787-802 (Pubitemid 47347450)
46. Karlsson J, Ungell A, Grasjo J, et al. Paracellular drug transport across intestinal epithelia: influence of charge and induced water flux. Eur J Pharm Sci 1999; 9 (1): 47-56 (Pubitemid 29430192)
47. Ungell AL, Nylander S, Bergstrand S, et al. Membrane transport of drugs in different regions of the intestinal tract of the rat. J Pharm Sci 1998; 87 (3): 360-6 (Pubitemid 28204591)
48. Piyapolrungroj N, Zhou YS, Li C, et al. Cimetidine absorption and elimination in rat small intestine. Drug Metab Dispos 2000; 28 (1): 65-72 (Pubitemid 30027514)
49. He H, Tran P, Yin H, et al. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos 2009; 37 (3): 536-44
50. He H, Tran P, Yin H, et al. Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs. Drug Metab Dispos 2009; 37 (3): 545-54
51. He YL, Wang Y, Bullock JM, et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol 2007; 47 (5): 633-41 (Pubitemid 46632151)
52. He YL, Sabo R, Picard F, et al. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes. Curr Med Res Opin 2009; 25 (5): 1265-72
53. Serra D, He YL, Bullock J, et al. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with type 2 diabetes. Int J Clin Pharmacol Ther 2008; 46 (7): 349-64 (Pubitemid 352005928)
54. Jaakkola T, Laitila J, Neuvonen PJ, et al. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol 2006; 99: 44-51 (Pubitemid 44034394)
55. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004; 64: 1339-58 (Pubitemid 38916346)
56. Niemi M, Backman JT, Neuvonen M, et al. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther 2001; 69: 400-6 (Pubitemid 32554545)
57. Niemi M, Cascorbi I, Timm R, et al. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 2002; 72: 326-32
58. Kirchheiner J, Brockmoller J, Meineke I, et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 2002; 71: 286-96 (Pubitemid 34311458)
59. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37: 1053-9 (Pubitemid 32304003)
60. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressurelowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410-9 (Pubitemid 40973424)
61. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253-9
62. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97
63. UKProspective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-13
64. Johnson ML, Singh H. Patterns of antihypertensive therapy among patients with diabetes. J Gen Intern Med 2005; 20: 842-6 (Pubitemid 41725700)
65. He YL, Ligueros-Saylan M, Sunkara G, et al. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. J Clin Pharmacol 2008; 48 (1): 85-95 (Pubitemid 350292271)
66. Meredith PA, Elliott HL. Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet 1992 Jan; 22 (1): 22-31
67. Mistry NB, Westheim AS, Kjeldsen SE. The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials. Expert Opin Pharmacother 2006; 7 (5): 575-81
68. Anderson VR, Perry CM, Robinson DM. Ramipril: a review of its use in preventing cardiovascular outcomes in high-risk patients. Am J Cardiovasc Drugs 2006; 6 (6): 417-32 (Pubitemid 46072401)
69. DREAM Trial Investigators; Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006 Oct 12; 355 (15): 1551-62 (Pubitemid 44550032)
70. Meisel S, Shamiss A, Rosenthal T. Clinical pharmacokinetics of ramipril. Clin Pharmacokinet 1994 Jan; 26 (1): 7-15 (Pubitemid 24029184)
71. Vickers S, Duncan CA, Chen IW, et al. Metabolic disposition studies on simvastatin, a cholesterol lowering prodrug. Drug Metab Disp 1990; 18: 138-45 (Pubitemid 20107705)
72. Prueksaritanont T, Gorham LM, Bennett MA, et al. In vitro metabolism of simvastatin in humans: identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997; 25: 1191-9 (Pubitemid 27446590)
73. Prueksaritoanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxyl acid is mediated primarily by CYP3A and not CYP2D6. Br J Clin Pharmacol 2003; 56: 120-4 (Pubitemid 36886497)
74. Ayalasomayajula SP, Dole K, He YL, et al. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. Curr Med Res Opin 2007; 23 (12): 2913-20
75. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80 (6): 565-81 (Pubitemid 44908269)
76. Gruer PJ, Vega JM, Mercuri MF, et al. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 1999; 84 (7): 811-5 (Pubitemid 29469791)
77. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41 (5): 343-70 (Pubitemid 34713089)
78. Eichhorn EJ, Gheorghiade M. Digoxin. Prog Cardiovasc Dis 2002; 44: 251-66 (Pubitemid 34438285)
79. Gheorghiade M, van Veldhuisen DJ, Colucci WS. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation 2006; 113: 2556-64 (Pubitemid 43948035)
80. Ostgren CJ, Merlo J, Rastam L, et al. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabetes Obes Metab 2004; 6: 367-74 (Pubitemid 39172859)
81. Lip GY, Varughese GI. Diabetes mellitus and atrial fibrillation: perspectives on epidemiological and pathophysiological links. Int J Cardiol 2005; 105: 319-21 (Pubitemid 41613592)
82. Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 2005; 105: 315-8 (Pubitemid 41605083)
83. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 147-53
84. Tanigawara Y, Okamura N, Hirai M, et al. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 1992; 263: 840-5
85. Fromm MF, Kim RB, Stein CM, et al. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999; 99: 552-7 (Pubitemid 29061872)
86. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324: 1865-75
87. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005; 44: 1227-46 (Pubitemid 41832565)
88. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001; 40: 587-603 (Pubitemid 32758581)
89. Black DJ, Kunze KL, Wienkers LC, et al. Warfarin-fluconazole: II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996; 24: 422-8
90. Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992; 5: 54-9
91. Serlin MJ, Breckenridge AM. Drug interactions with warfarin. Drugs 1983; 25: 610-20 (Pubitemid 13095560)
92. He YL, Sabo R, Riviere GJ, et al. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin 2007; 23 (5): 1131-8 (Pubitemid 46799597)
93. O'Reilly RA, Goulart DA, Kunze KL, et al. Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin Pharmacol Ther 1992; 51: 656-67
94. Cropp JS, Bussey HI. A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy 1997; 17: 917-28 (Pubitemid 27415096)
95. He YL, Sabo R, Campestrini J, et al. The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers. Br J Clin Pharmacol 2008; 65 (3): 338-46 (Pubitemid 351316915)
96. Cusack BJ. Pharmacokinetics in older persons. Am J Geriatr Pharmacother 2004; 2: 274-302 (Pubitemid 40378782)
97. Muhlberg W, Platt D. Age-dependent changes of the kidneys: pharmacological implications. Gerontology 1999; 45: 243-53 (Pubitemid 29408280)
98. He YL, Flannery B, Wang Y, et al. The influence of renal impairment on the pharmacokinetics of vildagliptin [abstract]. Clin Pharmacol Ther 2007; 81 Suppl. 1: S113
99. Lukashevich V, Schweizer A, Shao Q, et al. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 2011; 13 (10): 947-54
100. Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease: an update. Clin Pharmacokinet 1995; 29: 370-91
101. Rodighiero V. Effects of liver disease on pharmacokinetics: an update. Clin Pharmacokinet 1999; 37: 399-431
102. Williams RL, Mamelok RD. Hepatic disease and drug pharmacokinetics. Clin Pharmacokinet 1980; 5: 528-47 (Pubitemid 11170456)
103. He YL, Sabo R, Campestrini J, et al. The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Eur J Clin Pharmacol 2007; 63 (7): 677-86 (Pubitemid 46911348)
104. Hu P, Yin Q, Deckert F, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. J Clin Pharmacol 2009; 49 (1): 39-49
105. He YL, Yamaguchi M, Ito H, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes. Int J Clin Pharmacol Ther 2010; 48 (9): 582-95
106. Ahren B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002; 25 (5): 869-75 (Pubitemid 41094285)
107. Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-Hydroxy-1-adamantyl)- amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003; 46 (13): 2774-89 (Pubitemid 36702545)
108. Burkey BF, Russell M, Wang K, et al. Vildagliptin displays slow tight-binding to dipeptidyl peptidase (DPP)-4, but not DPP-8 or DPP-9 [abstract]. Diabetologia 2006; 49 Suppl. 1: 477-8
109. Marfella R, Barbieri M, Grella R, et al. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complications 2010; 24 (2): 79-83
110. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4888-94 (Pubitemid 41159387)
111. Ahren B, Landin-Olsson M, Jansson P-A, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89 (5): 2078-84 (Pubitemid 38619835)
112. Azuma K, RádikováZ, Mancino J, et al. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 2008; 93 (2): 459-64 (Pubitemid 351240816)
113. Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007; 92 (4): 1249-55 (Pubitemid 46556394)
114. Meier JJ, Nauck MA. GIP as a potential therapeutic agent? Horm Metab Res 2004; 36 (11-12): 859-66 (Pubitemid 40115911)
115. Meier JJ, Gallwitz B, Kask B, et al. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes 2004 Dec; 53 Suppl. 3: S220-4 (Pubitemid 39564547)
116. Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagonlike peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 2004 Dec; 53 Suppl. 3: S190-6 (Pubitemid 39564543)
117. Meier JJ, Gallwitz B, Siepmann N, et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003 Jun; 46 (6): 798-801 (Pubitemid 36831408)
118. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002 Mar; 87 (3): 1239-46 (Pubitemid 36121094)
119. Schirra J, Wank U, Arnold R, et al. Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans. Gut 2002; 50 (3): 341-8 (Pubitemid 34161049)
120. Vella A, Bock G, Giesler PD, et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 2007; 56 (5): 1475-80 (Pubitemid 46715627)
121. D'Alessio DA, Denney AM, Hermiller LM, et al. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J Clin Endocrinol Metab 2009 Jan; 94 (1): 81-8
122. Mari A, Schmitz O, Gastaldelli A, et al. Meal and oral glucose tests for assessment of b-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 2002; 283: E1159-66 (Pubitemid 35340621)
123. Bonadonna RC, Stumvoll M, Fritsche A, et al. Altered homeostatic adaptation of first-and second-phase b-cell secretion in the offspring of patients with type 2 diabetes: studies with a minimal model to assess b-cell function. Diabetes 2003; 52: 470-80 (Pubitemid 36173205)
124. Jackson RA, Blix PM, Matthews JA, et al. Comparison of peripheral glucose uptake after oral glucose loading and a mixed meal. Metabolism 1983; 32 (7): 706-10 (Pubitemid 13071707)
125. Mari A, Scherbaum WA, Nilsson PM, et al. Characterization of the influence of vildagliptin on model-assessed beta-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab 2008 Jan; 93 (1): 103-9
126. Scherbaum WA, Schweizer A, Mari A, et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008 Nov; 10 (11): 1114-24
127. Foley JE, Ligueros-Saylan M, He YL, et al. Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes. Horm Metab Res 2008; 40 (10): 727-30
128. Muller WA, Faloona GR, Aguilar-Parada E, et al. Abnormal alpha-cell function in diabetes: response to carbohydrate and protein ingestion.NEngl J Med 1970; 283 (3): 109-15
129. Aronoff SL, Bennett PH, Unger RH. Immunoreactive glucagon (IRG) responses to intravenous glucose in prediabetes and diabetes among Pima Indians and normal Caucasians. J Clin Endocrinol Metab 1977; 44 (5): 968-72 (Pubitemid 8104646)
130. Ohneda A, Watanabe K, HorigomeK, et al. Abnormal response of pancreatic glucagon to glycemic changes in diabetes mellitus. J Clin Endocrinol Metab 1978; 46 (3): 504-10 (Pubitemid 8305068)
131. Ahrén B, Schweizer A, Dejager S, et al. Vildagliptin enhances islet responsiveness to both hyper-and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009; 94 (4): 1236-43